Introduction {#Sec1}
============

Previous studies showed an association of the common C34T polymorphism in the *AMPD1* gene with survival in patients with heart failure (HF) and coronary artery disease (CAD). Adenosine monophosphate deaminase (AMPD, EC 3.5.4.6) catalyzes the deamination of adenosine monophosphate (AMP) to inosine monophosphate (IMP). The *AMPD1* gene located at 1p13 encodes isoenzyme which expresses the highest activity in skeletal muscles (Morisaki et al. [@CR32]). The *AMPD2* and *AMPD3* genes encode liver and erythrocyte isoenzyme, respectively. The *AMPD1* gene sequence consists of 22,455 base pairs (bp) including 16 exons (RefSeq NG_008012) (Sabina et al. [@CR38]). 2,341-bp mRNA (RefSeq NM_000036.1) encodes the 747-aa protein (RefSeq NP_000027.1, Swiss-Prot P23109).

The common C34T (Gln12Stop, rs17602729) polymorphism in the *AMPD1* gene results in a premature stop codon in exon 2, and, thus, in an inactive enzyme. T34 allele frequency in Europeans amounts to 10--15% (Morisaki et al. [@CR33]; Norman et al. [@CR36]). About 2% of Europeans are 34TT homozygotes (Norman et al. [@CR36]). For many years, the lack of AMPD activity in muscles was considered as the cause of myopathy (MIM 102770) (Sabina et al. [@CR37]). However, subsequent studies showed that most subjects with 34TT genotype, in spite of no detectable activity of AMPD in muscles, did not present any myopathy symptoms (Gross [@CR18]).

C34T mutation is linked with C143T (rs61752479, Pro48Leu) substitution in exon 3, which does not affect enzyme function in vitro (Morisaki et al. [@CR33]), but it is difficult to estimate its influence in vivo due to the linkage disequilibrium with C34T. Less frequent *AMPD1* mutations were found in exons 5 (G468T, Gln156His) (Gross et al. [@CR19]; Fischer et al. [@CR11]) and 7 (A860T, Lys287Ile, rs34526199) (Toyama et al. [@CR40]). Additionally, mutations in exons 3 (A44G, Asp15Gly) (Gross et al. [@CR19]), 8 (G930T, Met310Ile) (Toyama et al. [@CR40]), 9 (C1162T, Arg388Trp), and 10 (G1274A, Arg425His) (Morisaki et al. [@CR35]), as well as splice site deletion in intron 2 IVS2-(4-7)delCTTT (Isackson et al. [@CR24]), resulting in an enzyme with very low or no activity, were described in single patients or families.

Some reports suggested that T34 allele was associated with improved outcome in patients with HF (Loh et al. [@CR29]; Gastmann et al. [@CR15]; Yazaki et al. [@CR43]) and improved cardiovascular survival in patients with CAD (Anderson et al. [@CR3]), while other reports did not confirm such associations (Andreassi et al. [@CR4]; Kolek et al. [@CR27]; de Groote et al. [@CR9]). The results of the Collins et al. study ([@CR8]) suggested that the T34 allele was associated with poorer outcome in patients with a history of myocardial infarction. No previous reports analyzed the associations of other polymorphisms in the *AMPD1* gene with the phenotype of cardiovascular diseases.

Metabolic syndrome including obesity and diabetes is a major risk factor for CAD. The association of *AMPD1* C34T mutation with components of the metabolic syndrome in Polish patients with cardiovascular diseases was previously analyzed (Safranow et al. [@CR39]). The aim of the current study was to search for other mutations in selected regions of the *AMPD1* gene in Polish patients with CAD or HF, as well as in newborns treated as the genetic control group, and to analyze their associations with obesity and diabetes. We also investigated the linkage disequilibrium between the *AMPD1* mutations and sequence alterations of neighboring genes.

Materials and methods {#Sec2}
=====================

The study groups comprised of patients treated at the Department of Cardiology, Pomeranian Medical University in Szczecin, in the years 2004--2006. The patients were all of Polish descent and most of them were from Szczecin and its nearby neighborhood (North-Western Poland). The patients included in this study were clinically stable, with optimal pharmacological treatment and no acute coronary syndromes, HF exacerbations, or revascularization procedures within the last month. This study was approved by the institutional Ethics Committee. Informed consent was obtained from each patient.

CAD diagnosis was based on coronary angiography. The criteria for HF diagnosis included the presence of clinical symptoms, HF features in echocardiography, and elevated plasma B-type natriuretic peptide (BNP) concentration. Patients with hemodynamically significant congenital or acquired valve diseases were excluded.

The CAD+ HF− group comprised 97 patients aged 58.2 ± 8.6 years (77% men) with CAD (duration of symptoms 6.2 ± 5.9 years, 67% with past myocardial infarct) but without HF. The HF+ group comprised 104 patients aged 58.9 ± 9.6 years (79% men) with HF (duration of symptoms 4.7 ± 5.0 years, New York Heart Association \[NYHA\] class 2.1 ± 0.8). In 70 patients (67%), the etiology of HF was ischemic, in 23 (22%) it was non-ischemic, and in 11 patients (11%) it was complex.

The control group consisted of 200 consecutive newborns (96 males) of Polish origin born at the Department of Neonatology, Pomeranian Medical University in Szczecin, in the years 2004--2005. DNA was isolated from their umbilical cord blood.

Genotyping {#Sec3}
----------

Genomic DNA was extracted from 0.15 mL of K~3~EDTA-anticoagulated blood with a QIAamp DNA Mini Kit (QIAGEN). The previously described polymerase chain reaction--restriction fragment length polymorphism (PCR-RFLP) method with *Tai I* restriction enzyme was used to detect C34T substitution in exon 2 of the *AMPD1* gene (Safranow et al. [@CR39]).

For denaturing high-performance liquid chromatography (DHPLC) analysis and for direct sequencing of exons 2, 3, 5, and 7, DNA was amplified by PCR using exon-flanking primers (Table [1](#Tab1){ref-type="table"}). The reaction was carried out in a total volume of 25 μL containing: 40 ng of template DNA, 7.5 pmol of each primer (HPSF, MWG-Biotech AG), PCR buffer (10 mM Tris-HCl, 50 mM KCl, pH = 8.9), 2 mM MgCl~2~, 5 nmol of each dNTP, and 0.3 U of *Taq* polymerase (POLGEN). To minimize artifacts associated with replication errors of the exon 5 sequence, which contains a tract of 12 T nucleotides, high-fidelity Optimase (Transgenomic) polymerase with included buffer and 2.5 mM MgSO~4~ was used for this amplicon. The amplification was performed using the GeneAmp PCR System 9700 (Applied Biosystems) with initial denaturation at 94°C for 5 min and then 35 cycles as follows: denaturation at 94°C (30 s), annealing at 58°C for the first five cycles and 56°C for the subsequent 30 cycles (40 s), and extension at 72°C (45 s). The final 72°C incubation was extended by 5 min. The quality of PCR products was controlled by electrophoresis on 2% agarose gel stained with ethidium bromide, photographed in UV light. Table 1Primer sequences and denaturing high-performance liquid chromatography (DHPLC) temperature for the analysis of the *AMPD1* gene fragments*AMPD1* ampliconSense and antisense primerProduct length (bp)Optimal temperature of DHPLC separation (°C)Exon 25′-ATTCCCAAGCTTTCTGATGG-3′210575′-CTCTGACAAATGGCAGCAAA-3′Exon 35′-AGGGGCTTGAACACTAATATG-3′274615′-GGCAGATACCCCTCCTTAG-3′Exon 55′-TTTCGTGGGATTGACTCTGA-3′34159.55′-GGGGCCAAAGATGATTATGA-3′Exon 75′-GAATGCCTGAAACTTTTTGGA-3′222615′-GAATTGTTTTTGCCCAGGAA-3′

DHPLC analyses were performed with the Hewlett-Packard 1050/1100 system and a Helix DNA column (CP28353, Varian) (Kurzawski et al. [@CR28]). PCR products were denatured (95°C, 5 min) and reannealed by slowly decreasing the temperature (1°C/min) to allow the formation of heteroduplexes. Then, a 5--10-μL sample was injected into the column. The optimal temperature for the analysis of heteroduplexes was initially calculated with the DHPLC Melt Program (<http://insertion.stanford.edu/melt.html>) (Jones et al. [@CR25]) and subsequently adjusted based on experiments to achieve optimal separation of the homo- and heteroduplexes for each amplicon (Table [1](#Tab1){ref-type="table"}).

Samples with DHPLC profiles different from wild-type homozygote were directly sequenced in the forward and reverse directions with the ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction (Applied Biosystems) according to the manufacturer's protocols. Sequences were read with the DNA 377 or 3130 analyzer (Applied Biosystems).

Bioinformatics {#Sec4}
--------------

Protein and DNA sequences of the *AMPD1* gene in human and 27 other vertebrates were compared using the University of California Santa Cruz (UCSC) Genome Browser (<http://genome.ucsc.edu/>). We analyzed the genomes of *Homo sapiens* (NCBI sequence version 36.1), 19 mammals (*Pan troglodytes*, *Macaca mulatta*, *Otolemur garnettii*, *Tupaia belangeri*, *Mus musculus*, *Rattus norvegicus*, *Cavia porcellus*, *Oryctolagus cuniculus*, *Sorex araneus*, *Erinaceus europaeus*, *Canis familiaris*, *Felis catus*, *Bos taurus*, *Equus caballus*, *Dasypus novemcinctus*, *Loxodonta africana*, *Echinops telfairi*, *Monodelphis domestica*, *Ornithorhynchus anatinus*), lizard (*Anolis carolinensis*), chicken (*Gallus gallus*), frog (*Xenopus tropicalis*), and five fish species (*Danio rerio*, *Tetraodon nigroviridis*, *Takifugu rubripes*, *Gasterosteus aculeatus*, *Oryzias latipes*). Analyses of some loci were limited to a lower number of species when the sequence data were not available.

The BLASTP 2.2.18 program (Altschul et al. [@CR2]) was used to compare human amino acid sequences with invertebrates and other species. Exonic splicing enhancer (ESE) and exonic splicing silencer (ESS) sequences were searched with the ESEfinder (Cartegni et al. [@CR6]) and FAS-ESS (Wang et al. [@CR41]) programs. Linkage disequilibrium between *AMPD1* C34T mutation and polymorphisms of other genes located in its vicinity were analyzed using the HapMap database (version 23a) (International HapMap Consortium [@CR23]).

Statistical analysis {#Sec5}
--------------------

Genotype and allele frequencies as well as other qualitative variables were analyzed with Fisher's exact test (two-sided) implemented in the SISA Tables program (Quantitative Skills) (Agresti [@CR1]). The exact test was also applied to assess the conformity of the genotype distribution to the Hardy--Weinberg law (Guo and Thompson [@CR20]). When tables were too large for exact tests, the χ^2^ test was used. Confidence intervals for allele frequencies were calculated with the exact test (Clopper and Pearson [@CR7]). Quantitative variables were compared between genotype groups with the Mann--Whitney test.

Haplotype and linkage disequilibrium analyses were performed with the HaploView 4.0 program (Barrett et al. [@CR5]). Lewontin's D′ value, its 95% confidence interval, *r* ^2^, and LOD score were calculated for each loci pair.

Results {#Sec6}
=======

Genotype data {#Sec7}
-------------

No deviation from the Hardy--Weinberg equilibrium (*p* \> 0.05) was observed for the *AMPD1* genotypes in the two study groups and in the controls (Table [2](#Tab2){ref-type="table"}). Mutated 860T allele was less frequent in both study groups than in the controls, and the difference between the combined CAD+ HF− and HF+ group (*n* = 201) and newborns reached statistical significance (1.7 vs. 4.3%, *p* = 0.040). No other significant differences in the *AMPD1* genotype and allele frequencies were found between the three groups. Table 2Frequency distribution of *AMPD1* sequence alterations in patients with coronary artery disease without heart failure (CAD+ HF−, *n* = 97), patients with heart failure (HF+, *n* = 104), newborn controls (*n* = 200), and all combined groups (*n* = 401)Polymorphism/groupGenotype frequency (%)*p*-value^a^Minor allele frequency (95%CI)^b^ (%)*p*-value^c^HWE *p*-value^d^C34TCCCTTTTCAD+ HF−70.123.76.20.2918.0 (12.9--24.2)0.700.076HF+71.126.02.915.9 (11.2--21.6)0.72Newborns70.528.01.515.5 (12.1--19.4)0.43All70.626.43.016.2 (13.7--19.0)0.58C143TCCCTTTTCAD+ HF−69.124.76.20.3018.6 (13.4--24.8)0.670.088HF+71.126.02.915.9 (11.2--21.6)0.72Newborns70.028.51.515.7 (12.3--19.7)0.43All70.126.93.016.5 (14.0--19.2)0.72G512AGGGAAAACAD+ HF−95.94.100.162.1 (0.6--5.2)0.161.0HF+98.11.901.0 (0.1--3.4)1.0Newborns99.01.000.5 (0.1--1.8)1.0All98.02.001.0 (0.4--2.0)1.0A860TAAATTTCAD+ HF−95.94.100.122.1 (0.6--5.2)0.131.0HF+97.12.901.4 (0.3--4.2)1.0Newborn91.58.504.3 (2.5--6.7)1.0All94.06.003.0 (1.9--4.4)1.0^a^For all genotype frequencies in the three groups^b^95% confidence interval for minor allele frequency^c^For allele frequencies in the three groups^d^Exact test for deviation of genotype frequencies from the Hardy--Weinberg equilibrium

Due to linkage disequilibrium, the T allele in locus 34 was almost always accompanied by the T allele in locus 143, except for two subjects with the 34CC-143CT genotype. There were two subjects with the 34CT-143CT genotype and concomitant G512A substitution and one with a 34CT-143CT-860AT combination. All other 512A and 860T alleles were detected in 34CC-143CC homozygotes.

Three new variants were found and confirmed by direct sequencing. Synonymous substitution A99G (Gly33Gly) in exon 3 was detected in two newborns (99G allele frequency: 0.25%, 95%CI: 0.03--0.9%). It was added to the dbSNP recently as rs61752480. Deletion IVS4-6delT in intron 4, which results in truncation of the T-tract located just before the start of exon 5 from 12T to 11T, was found in one allele of a newborn (IVS4-6delT allele frequency: 0.12%, 95%CI: 0.003--0.7%). Substitution C784T (Arg262Trp) in exon 7 was detected in one allele of a CAD+ HF− patient (784T allele frequency: 0.12%, 95%CI: 0.003--0.7%).

The haplotypes consisting of seven polymorphic sites, estimated using expectation--maximization algorithm, are shown in Table [3](#Tab3){ref-type="table"}. No significant differences in the *AMPD1* haplotype distribution were found between groups. The frequency of the major haplotype was 79.1% in the combined groups (*n* = 401). The haplotype carrying the 34T allele had a frequency of 16.2% and the remaining haplotypes were at 4.7%. Table 3Frequency distribution of haplotypes comprising C34T, A99G, C143T, IVS4-6delT, G512A, C784T, and A860T *AMPD1* gene sequence alterations in patients with coronary artery disease without heart failure (CAD+ HF−, *n* = 97), patients with heart failure (HF+, *n* = 104), and newborn controls (*n* = 200).HaplotypeGroupC34TA99GC143TIVS4 -6delTG512AC784TA860TCAD+ HF−HF+NewbornsCACTGCA149 (76.8%)170 (81.7%)315 (78.8%)**T**A**T**TGCA35 (18.0%)33 (15.9%)62 (15.5%)CACTGC**T**4 (2.1%)3 (1.4%)17 (4.2%)CACT**A**CA4 (2.1%)2 (1.0%)2 (0.5%)CA**T**TGCA1 (0.5%)0 (0%)1 (0.25%)C**G**CTGCA0 (0%)0 (0%)2 (0.5%)CACTG**T**A1 (0.5%)0 (0%)0 (0%)CAC**-**GCA0 (0%)0 (0%)1 (0.25%)Alleles different from the wild type are shown in **bold***p* = 0.34, Chi-square test for all haplotype frequencies in the three groups

Obesity and diabetes {#Sec8}
--------------------

Table [4](#Tab4){ref-type="table"} compares parameters associated with the metabolic syndrome (obesity, history of diabetes, fasting glycemia) among wild-type (WT) homozygotes for all of the analyzed loci, 34CT heterozygotes, and 860AT heterozygotes. Due to the low number of 860T carriers (*n* = 7), the CAD+ HF− and HF+ groups were combined. Higher body mass index (BMI), prevalence of diabetes (particularly when combined with hyperglycemia), and abdominal obesity were observed in 860AT compared to 34CT heterozygotes. There was also a high proportion of women among 860AT patients. The presence of C34T mutation is associated with lower (odds ratio \[OR\] = 0.32, 95%CI = 0.13-0--81) and the presence of A860T with higher (OR = 13.7, 95%CI = 1.6--118) prevalence of diabetes or hyperglycemia in relation to wild-type homozygotes (34CT\<WT\<860AT). Table 4Comparison of clinical data in a combined group of CAD+ HF− and HF+ patients stratified according to the *AMPD1* genotype*AMPD1* genotypeWT (*n* = 128)34CT (*n* = 49)860AT (*n* = 7)Statistical significance^a^34CT vs. WT860AT vs. WT860AT vs. 34CTAge (years)59.3 ± 8.357.8 ± 9.759.1 ± 8.70.250.880.66Female gender26 (20%)9 (18%)4 (57%)0.84**0.0430.043**BMI (kg/m^2^)28.2 ± 4.327.1 ± 3.332.7 ± 7.70.210.087**0.046**Obesity (BMI ≥30 kg/m^2^)43 (34%)11 (22%)4 (57%)0.200.240.074Waist (cm)97.0 ± 11.393.8 ± 11.2104.3 ± 16.00.0670.180.072Waist ≥102 cm (males) or ≥88 cm (females)^b^51 (40%)14 (29%)6 (86%)0.22**0.0410.0064**Diabetes type 228 (22%)4 (8%)4 (57%)**0.048**0.054**0.0055**FPG ≥ 126 mg/dL32 (25%)6 (12%)2 (29%)0.0691.00.26Diabetes or FPG ≥ 126 mg/dL39 (30%)6 (12%)6 (86%)**0.0120.00560.00018**FPG -- fasting plasma glucose; WT -- wild-type for all analyzed loci^a^Fisher's exact test for qualitative variables and the Mann--Whitney test for quantitative variables; significant differences are shown in **bold**^b^Criterion of abdominal obesity according to NCEP ATP III ([@CR10])Data are given as mean ± standard deviation (SD) for quantitative variables or number (percentage) of patients with the indicated feature for qualitative variables

Linkage disequilibrium analysis of *AMPD1* C34T and SNPs in neighboring genes {#Sec9}
-----------------------------------------------------------------------------

Table [5](#Tab5){ref-type="table"} presents the linkage disequilibrium analysis of *AMPD1* C34T mutation and 1,728 single-nucleotide polymorphisms (SNPs) located in known genes at the distance of up to 1,000,000 base pairs downstream and upstream from C34T. It is based on HapMap data for the CEU population containing genotypes of 60 unrelated subjects of European descent, including 12 (20%) 34CT heterozygotes and two (3.3%) 34TT homozygotes. No other *AMPD1* sequence alterations described in the current paper were present in the HapMap database. Table 5Linkage analysis of *AMPD1* C34T polymorphism (position 115 037 580 on chromosome 1) and other polymorphisms (SNPs) located in known genes at the distance of up to 1,000,000 base pairs. LOD score and *r* ^2^ values for the most strongly linked polymorphism in each gene are shownGeneChromosome 1 locationNumber of SNPsNumber (%) of SNPs with LOD score \>2Maximal LOD scoreMaximal *r* ^2^*PHTF1*114 041 360 -- 114 102 879170 (0%)0.570.019*RSBN1*114 105 977 -- 114 156 593270 (0%)0.890.027*PTPN22*114 157 960 -- 114 215 857320 (0%)0.890.037*BCL2L15*114 220 959 -- 114 231 69290 (0%)0.470.016*AP4B1*114 239 201 -- 114 249 21580 (0%)0.370.019*DCLRE1B*114 249 561 -- 114 258 21760 (0%)0.220.008*HIPK1*114 273 519 -- 114 321 945240 (0%)0.340.017*OLFML3*114 323 553 -- 114 326 39830 (0%)0.420.021*LOC100132906*114 345 578 -- 114 347 48810 (0%)00*SYT6*114 433 437 -- 114 497 9951210 (0%)1.030.063*MRP63P1*114 623 147 -- 114 623 4310------*TRIM33*114 736 922 -- 114 855 304411 (2%)2.550.149*LOC643586*114 864 161 -- 114 881 992102 (20%)8.650.468*BCAS2*114 911 701 -- 114 925 78863 (50%)11.990.665*DENND2C*114 928 719 -- 115 014 2554219 (45%)11.990.665*AMPD1*115 017 245 -- 115 039 699127 (58%)11.990.665*NRAS*115 051 108 -- 115 061 03832 (67%)8.930.332*CSDE1*115 061 060 -- 115 102 147257 (28%)13.070.585*SIKE*115 113 623 -- 115 124 83130 (0%)1.490.049*NR1H5P*115 178 857 -- 115 199 038175 (29%)6.720.223*SYCP1*115 198 978 -- 115 339 5147749 (64%)9.080.45*TSHB*115 373 938 -- 115 378 46464 (67%)3.870.157*TSPAN2*115 392 155 -- 115 433 6387943 (54%)7.330.343*NGF*115 630 060 -- 115 682 3801000 (0%)1.130.056*LOC100132332*115 908 526 -- 115 909 5760------*VANGL1*115 986 097 -- 116 042 368910 (0%)1.180.051*PHTF1* -- putative homeodomain transcription factor 1; *RSBN1* -- round spermatid basic protein 1; *PTPN22* -- protein tyrosine phosphatase, non-receptor type 22 (lymphoid); *BCL2L15* -- BCL2-like 15; *AP4B1* -- adaptor-related protein complex 4, beta 1 subunit; *DCLRE1B* -- DNA cross-link repair 1B (PSO2 homolog); *HIPK1* -- homeodomain interacting protein kinase 1; *OLFML3* -- olfactomedin-like 3; *LOC100132906* -- similar to mCG23455, pseudogene; *SYT6* -- synaptotagmin VI; *MRP63P1* -- mitochondrial ribosomal protein 63 pseudogene 1; *TRIM33* -- tripartite motif-containing 33; *LOC643586* -- similar to pyruvate kinase, muscle, pseudogene; *BCAS2* -- breast carcinoma amplified sequence 2; *DENND2C* -- DENN/MADD domain containing 2C; *AMPD1* -- adenosine monophosphate deaminase 1; *NRAS* -- neuroblastoma RAS viral (v-ras) oncogene homolog; *CSDE1* -- cold shock domain containing E1; *SIKE* -- suppressor of IKK epsilon; *NR1H5P* -- nuclear receptor subfamily 1, group H, member 5 pseudogene; *SYCP1* -- synaptonemal complex protein 1; *TSHB* -- thyroid stimulating hormone, beta; *TSPAN2* -- tetraspanin 2; *NGF* -- nerve growth factor (beta polypeptide); *LOC100132332* -- similar to CCR4-NOT transcription complex, subunit 7, pseudogene; *VANGL1* -- vang-like 1 (van gogh, Drosophila)

A region with strong linkage ranges as far as 400,000 bp upstream of the *AMPD1* gene, up to the *TSPAN2* gene. After the exclusion of pseudogenes, nine genes (*TRIM33*, *BCAS2*, *DENND2C*, *NRAS*, *CSDE1*, *SIKE*, *SYCP1*, *TSHB*, *TSPAN2*) contain polymorphisms linked with the *AMPD1* C34T mutation. It cannot be excluded that one of these polymorphisms is directly responsible for the observed associations with obesity and diabetes, while *AMPD1* mutations are just genetic markers without functional connection to metabolic syndrome.

Discussion {#Sec10}
==========

In the current study, we analyzed selected exons of the *AMPD1* gene (where non-synonymous mutations leading to loss of muscle AMP deaminase activity had been described previously) in patients with cardiovascular diseases and in newborn controls. We chose exon 2 with the well-known C34T (Gln12Stop) mutation, exon 3 with equally frequent C143T (Pro48Leu) substitution, exon 5 with G468T (Gln156His) mutation found in the German population (Gross et al. [@CR19]), and exon 7 with A860T (Lys287Ile) (Toyama et al. [@CR40]) described in Europeans. The presence of the same genotype at loci 34 (RFLP method) and 143 (DHPLC) was an additional proof of correct genotyping: when the results were discordant, direct sequencing was performed to confirm the rare combination of genotypes at both loci.

Our results have shown that, in the Polish population, similarly to other Europeans, the most frequent alterations of the *AMPD1* coding sequence are C34T and C143T, which are strongly linked with each other. The most numerous group of Europeans genotyped for the *AMPD1* C34T mutation so far is a cohort of 2,707 healthy British subjects (Webb et al. [@CR42]) with the frequency of 34T allele equal to 13%, which is at the lower limit of confidence intervals for our groups (Table [2](#Tab2){ref-type="table"}). The 34T frequency in a group of 721 healthy subjects from south-western Germany was 14.5% (Frank et al. [@CR14]), while in 175 healthy Swedes, it was 13.7% (Norman et al. [@CR36]). It seems that the 34T allele frequency is similar in various European populations, including patients and newborns examined in the current study.

According to previous reports, A860T mutation is present in 3% alleles of healthy subjects of European descent (Toyama et al. [@CR40]). The 860T allele frequency was 2.6% in healthy Americans of European origin (Isackson et al. [@CR24]) and 2.8% in the healthy German population (Hanisch et al. [@CR22]). These values are in agreement with results of the current study (Table [2](#Tab2){ref-type="table"}). Four other detected sequence alterations (A99G in exon 3, IVS4-6delT in intron 4, G512A in exon 5, C784T in exon 7) have not been described previously.

We have not found any case of G468T mutation. This variant is probably very rare and limited to Germany, since it has not been detected in 230 subjects (healthy or with myopathy) from various populations (Toyama et al. [@CR40]) and in 704 healthy Swedes (Fischer et al. [@CR12]). Similarly, we have not found del404T mutation in exon 5, which was detected in two of 879 Swedes (Norman et al. [@CR36]; Fischer et al. [@CR12]).

The genotype combination 34TT+143CT was detected in 0.5% of subjects, which is similar to the 0.7% frequency found in Americans of European origin (Isackson et al. [@CR24]). Other previously described rare combinations (34CT+143CC and 34CT+143TT) (Fishbein et al. [@CR13]) were not found in our population.

Functional impact of detected *AMPD1* sequence alterations {#Sec11}
----------------------------------------------------------

Since our study did not involve the assessment of muscle AMP deaminase activity, we present the analysis of the possible impact of the detected alterations on enzyme function based on the previous reports and comparative genomics. The C34T mutation in exon 2 (Gln12Stop) definitely leads to the termination of translation and results in the lack of immunoreactive protein (Morisaki et al. [@CR33]) and enzyme activity (about 1% of normal) in homozygotes (Norman et al. [@CR36]). Alternative splicing excluding exon 2 may partly explain the residual AMPD activity and hypothetically protect from the metabolic consequences of the defect (Morisaki et al. [@CR34]), but this theory needs to be proven.

The C143T transition (Pro48Leu) in most cases accompanies C34T and has no functional meaning, since translation terminates at codon 12. However, it could be introduced into the protein if exon 2 was excluded due to alternative splicing. A study analyzing the expression of cDNA with 143T and 34C in *Escherichia coli* did not show altered enzyme activity (Morisaki et al. [@CR33]), but its stability and affinity were not analyzed, and the influence on human muscle AMPD activity is unknown. Proline is exceptionally conservative and present in all analyzed vertebrates at the position corresponding to Pro48 in human AMPD1, together with adjacent amino acids, forming the sequence Cys-Pro-Ile. This sequence is also present in the human AMPD3 protein and all of its orthologs in vertebrates, while in human AMPD2, the sequence is Ser-Pro-Ile. Proline is conservative also in AMPD proteins of non-vertebrates (Tyr-Pro-Ile sequence in *Caenorhabditis elegans*), and even in plants (*Arabidopsis thaliana*) (Han et al. [@CR21]). The adjacent AMPD1 region encompassing AA 51-60 is a putative zinc-binding site (Martini et al. [@CR31]) and has an α-helix structure (Mangani et al. [@CR30]). Proline-induced break of the α-helix may be important for proper spatial conformation of the Zn^2+^-binding domain. The remarkable evolutionary conservativeness of Pro48 needs further investigation, which could elucidate the effects of C143T substitution in the case of alternative splicing excluding exon 2.

A860T transversion (Lys287Ile) affects the AMPD1 region responsible for myosin binding. Lysine is totally conservative in the corresponding position of AMPD1, AMPD2, and AMPD3 proteins in vertebrates and in most non-vertebrates and plants. In some protozoa, lysine is substituted by arginine, a basic amino acid with similar properties. The recombined mutated protein has decreased both the activity and affinity for AMP by half in relation to wild-type enzyme (Toyama et al. [@CR40]). Two reported cases confirm impaired function of the mutated enzyme in vivo. The muscle AMPD activity in a subject with myopathy symptoms who turned out to be a compound heterozygote with IVS2-(4-7)delCTTT and A860T mutations was 20--25% of normal (Isackson et al. [@CR24]). Another compound heterozygote with C34T and A860T mutations had the activity equal to about 40% of common 34CT heterozygotes (Hanisch et al. [@CR22]). It seems that the activity of enzyme encoded by 860T allele is 40--50% in relation to the enzyme encoded by wild-type allele.

G512A transition (Gly171Asp) is the most frequent *AMPD1* alteration not described previously. Gly171 is fully conservative in all of analyzed AMPD1 proteins in mammals, chicken, frog, and fish, but it is substituted by asparagine in lizard. Mammal AMPD2 contains alanine and AMPD3 may contain alanine, glycine, or threonine. AMPDs in non-vertebrates contain such different amino acids as leucine, proline, and glutamate. These data suggest relatively low conservation and, possibly, the lack of functional impact of Gly171Asp alteration.

C784T (Arg262Trp) changes arginine residue, which is very conservative in AMPD1, AMPD2, and AMPD3 proteins of all 26 analyzed vertebrates, as well as in AMPD of insects, nematodes, and most fungi and plants (*Arabidopsis thaliana*). In some fungi and protozoa, arginine is substituted by similar basic lysine or histidine. Only a few protozoa contain other amino acids (glutamine, tyrosine, aspartate, glutamate). In FAC1 protein with AMPD activity in *A. thaliana*, the corresponding Arg (position 350 in the Swiss-Prot O80452 sequence) is located in an α-helix structure in the middle of the His-Arg-Arg sequence, which forms a positively charged flat surface (Han et al. [@CR21]). These facts suggest the high probability of functional impact of the C784T substitution.

The intron 4 region with IVS4-6delT alteration (cttttttttttt[t]{.ul}ggcagGTT) contains a typical splice acceptor sequence: pyrimidine-rich tract and "ag" at the intron--exon boundary. The deletion shortens the tract from 12 to 11 thymines. The chimpanzee *AMPD1* intron 4--exon 5 boundary is identical to the human sequence, but for the presence of 11T instead of 12T, just like in the human IVS4-6delT variant. In other primates, the pyrimidine-rich tract may be as short as 7 bp. These facts are evidence against the functional role of the deletion.

Synonymous A99G (Gly33Gly) transition in exon 3 deletes one of five ESE motifs specific for the SF2/ASF protein (AGG[A]{.ul}GGT) with relatively low score (2.43) and creates the ESS motif (AGG[G]{.ul}GG), but it does not affect the ESE motifs specific for other SR proteins (SC35, SRp40, SRp55). Adenine is present in eight of ten mammals as coding nucleotide 99, while guanine is found in two (rabbit and tenrec). It suggests that the A99G variant lacks functional significance.

*AMPD1* and cardiovascular diseases {#Sec12}
-----------------------------------

Similarly to all earlier studies, we did not find significant differences in the C34T polymorphism genotype distributions in the study groups (CAD+ HF− and HF +) and in a random control group consisting of consecutive newborns from the same population as the study groups (Table [2](#Tab2){ref-type="table"}). The T34 allele does not prevent the development of either CAD or HF, though it seems to protect from the known risk factors of CAD, such as abdominal obesity and diabetes (Safranow et al. [@CR39]). We did not find significant differences between groups for the other detected sequence alterations, but the 860T allele was less frequent in a combined group of patients than in newborns. It could be interpreted as a protective effect of the T allele against cardiovascular diseases, but such a hypothesis should be treated with caution due to the low number of 860T carriers and moderate statistical significance.

*AMPD1* and diabetes {#Sec13}
--------------------

It was reported that variation in the *AMPD1* gene is associated with insulin clearance and may participate in the syndromes of insulin resistance (Goodarzi et al. [@CR17]). In the previous paper (Safranow et al. [@CR39]), we demonstrated that the carriage of T34 mutated allele in CAD patients without HF is associated with a lower prevalence of two features of metabolic syndrome, diabetes and obesity, while in patients with HF, it is associated with lower fasting glucose. Hypothetically, the activity of AMPD can influence the activity of AMP-activated protein kinase (AMPK), which controls cellular energy balance (e.g., by stimulating cellular glucose uptake), affecting the development of type 2 diabetes in many ways (Gerbitz et al. [@CR16]). In this study, we compared the influence of C34T and A860T mutations on obesity and diabetes in a combined group of patients with and without HF. Surprisingly, their effect proved opposite: 34CT heterozygotes had a significantly lower frequency of diabetes than wild-type homozygotes, but in 860AT heterozygotes, the prevalence of diabetes and obesity was higher than in WT and 34CT patients. These differences were particularly significant when the presence of diabetes or fasting plasma glucose ≥126 mg/dL was analyzed (12% vs. 30% vs. 86% prevalence for 34CT, WT, and 860AT, respectively). The difference in metabolic effects of the two mutations might be explained by the different ways of enzyme protein modification: termination of translation by C34T and reduction of the activity by 40--50% in the case of A860T. Alternatively, the explanation might be the linkage disequilibrium of *AMPD1* mutations with functional variants in neighboring genes.

Linkage analysis of *AMPD1* C34T polymorphism {#Sec14}
---------------------------------------------

Since the *AMPD1* gene is expressed at a high level only in skeletal muscles, the mechanisms of genotype--phenotype association between its mutations and clinical features of patients with cardiovascular diseases remain unclear. Therefore, a possibility of linkage with unknown sequence alteration within another gene should be taken into account. The nine genes containing polymorphisms linked with *AMPD1* C34T mutation (Table [5](#Tab5){ref-type="table"}) play various roles, and in most cases, their function is poorly understood. *TRIM33* encodes transcription corepressor. *BCAS2* is expressed in breast tumors, interacting with estrogen receptors. *DENND2C* encodes protein with the DENN domain and unknown function. Other proteins containing the DENN domain participate in mitogen-activated protein kinases (MAPK) pathways. Membrane protein encoded by *NRAS* oncogene plays a part in MAPK pathways and in signaling through insulin receptor. Unr protein encoded by *CSDE1* gene is an RNA chaperon, *SIKE* participates in the inhibition of interferon secretion during viral infection, and *SYCP1* codes for synaptonemal transverse filament protein. *TSPAN2* encodes a membrane protein classified as one of the tetraspanins, which participate in the transduction of signals controlling cell development, activation, growth, and movement. *TSHB* encoding the beta subunit of thyrotropic hormone (TSH) is particularly interesting, since its mutations lead to congenital secondary hypothyroidism (Karges et al. [@CR26]), while both hypo- and hyperthyroidism are recognized risk factors for cardiovascular diseases. We have not found any reports analyzing the association between polymorphisms of the above-mentioned genes and cardiovascular diseases.

Conclusions {#Sec15}
===========

The most frequent mutation of the *AMPD1* gene in the Polish population is the C34T substitution, associated with reduced prevalence of diabetes and obesity in patients with coronary artery disease (CAD) or heart failure (HF). The A860T mutation seems to exert metabolic effects differing from C34T and should always be accounted for in studies of the *AMPD1* genotype. The potential association of this mutation with reduced risk of cardiovascular disease, as well as with increased prevalence of obesity and diabetes, merits further study in a larger population of patients. Due to the strong linkage of *AMPD1* mutations with sequence alterations in the *TRIM33*, *BCAS2*, *DENND2C*, *NRAS*, *CSDE1*, *SIKE*, *SYCP1*, *TSHB*, and *TSPAN2* genes, it seems prudent to analyze the effect of these alterations on the associations between clinical and metabolic parameters and the *AMPD1* genotype.
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